WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that the following will be reported at the Annual Meeting of the American Association for Cancer Research (AACR), to be held April 12-16, 2008 in San Diego, CA:
